Clinical Trial: Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies

U.S., Sept. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07193420) titled 'Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies' on July 11.

Brief Summary: Phase III comparative, open-label, randomized (1:1) trial designed to evaluate the efficacy of reducing the total dose of PTCy to 70 mg/kg on GREFS compared to the standard dose of 100 mg/kg, in patients undergoing haploidentical HSCT for the treatment of a hematological malignancy, two years after HSCT.

Study Start Date: Sept., 2025

Study Type: INTERVENTIONAL

Condition: GVHD - Graft-Versus-Host Disease HSCT Haploidentical Stem Cell Transplantation...